← Leaderboards
Scott William John McPhee
Asklepios Biopharmaceutical, Inc.
$3,874,685
Attributed
$3,874,685
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3M · FY2008–14$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$3,874,685 · 4
By mechanism
RC3$2,999,988 · 1
U44$320,999 · 1
R43$283,690 · 1
R41$270,008 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Safety”
- David Heimbrook · Leidos Biomedical Research, Inc.$398,099,186
- Lawrence Corey · Fred Hutchinson Cancer Center$396,952,463
- Mitchell J Malone · Texas A&M Research Foundation$329,191,208
- Gary D Acton · University Of California-Davis$320,373,312
- Melynda Holmes · Technical Resources Inc$232,659,786
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
Research focus
SafetyVectorGenesDosePre-ClinicalMediatingResearch StudyGene TherapyAnimal ModelBasePreclinical StudyTransgenesDependovirusResponseGene TransferSuccessFeasibility StudiesBiological ProductsClinical TrialsToxicologyAdeno-Associated Viral VectorProtocols DocumentationPhenotypePerformance
Grant awards (5)
AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease$270,008
R41 · FY2014 · AG · contact PI
Self-Complementary AAV2 Factor IX for Hemophilia B$2,999,988
RC3 · FY2010 · HL · contact PI
Preclinical Studies Supporting Phase Ib Study of Minidystrophin Gene in AAV Vecto$1
U44 · FY2010 · NS · contact PI
Preclinical Studies Supporting Phase Ib Study of Minidystrophin Gene in AAV Vecto$320,998
U44 · FY2008 · NS · contact PI
Preclinical Development of AAV-Galanin for Epilepsy$283,690
R43 · FY2008 · NS · contact PI